Vertex and Lonza plan to open a new facility to support the manufacturing of type 1 diabetes (T1D) cell therapies.
The new facility is planned to cover an expansive area of more than 130,000 square feet. The new dedicated facility will serve as a valuable addition to global network for manufacturing cell and gene technologies.
Its primary purpose will revolve around providing unwavering support for the production of Vertex's array of experimental insulin-producing islet cell therapies, derived from stem cells and fully differentiated.
The current focus of the facility lies on advancing the VX-880 and VX-264 programmes, both of which are presently undergoing clinical trials.
This network plays a pivotal role in aiding clients in of developing, mitigating risks, commercialising, and expanding the reach of their nascent therapeutic endeavours.
As this new manufacturing facility comes to fruition, it is expected to generate employment opportunities, potentially amounting to as many as 300 positions during the peak capacity phase.
The commencement of construction is slated for later in the ongoing year.
Vertex and Lonza